Currently a pharmacy resident in innovation and research, I am completing a master 2 in pharmacokinetics applied to oncology and will pursue next year as a pH.D student. My project consists in researching constitutional biomarkers in acute myeloid leukemia patients treated with cytarabine. Thus, I work on a clinical trial to determine cytarabine level in plasma and its pharmacokinetic profile. Phenotypic and genotypic approaches are being used to evaluate the activity of two enzymes of cytarabine metabolism: CDA and DCK. A correlation between CDA/DCK activity and toxicity/response to treatment is expected.